In the CARE study, treatment with pravastatin significantly reduced the rate of a recurrent coronary event (either coronary heart disease death or non-fatal MI) by 24% (p = 0.003) and was associated with a decrease in the rate of coronary bypass surgery by 14.1% in the pravastatin group, compared to 18.8% in the placebo group (coronary bypass surgery or angioplasty).